Evidence map›Paper›PMID 25617766›Full record

ArticlePloS one2015

Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.

Mari Tinholt, Benedicte Stavik, William Louch, Cathrine Rein Carlson, Marit Sletten, Wolfram Ruf, Grethe Skretting, Per Morten Sandset, Nina Iversen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Syndecan-3 in Inflammation and Angiogenesis.Frontiers in immunology · 2019
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mari TinholtDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Haematology and Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Benedicte StavikDepartment of Haematology and Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
William LouchInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Cathrine Rein CarlsonInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Marit SlettenDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
Wolfram RufDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America.
Grethe SkrettingDepartment of Haematology and Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Per Morten SandsetDepartment of Haematology and Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Nina IversenDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NOScripps Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTissue factor (TF) pathway inhibitor (TFPI) exists in two isoforms; TFPIα and TFPIβ. Both isoforms are cell surface attached mainly through glycosylphosphatidylinositol (GPI) anchors. TFPIα has also been proposed to bind other surface molecules, like glycosaminoglycans (GAGs). Cell surface TFPIβ has been shown to exert higher anticoagulant activity than TFPIα, suggesting alternative functions for TFPIα. Further characterization and search for novel TFPI binding partners is crucial to completely understand the biological functions of cell associated TFPI. METHODS AND

resultsPotential association of TFPI to heparan sulphate (HS) proteoglycans in the syndecan family were evaluated by knock down studies and flow cytometry analysis. Cell surface colocalization was assessed by confocal microscopy, and native PAGE or immunoprecipitation followed by Western blotting was used to test for protein interaction. Heparanase was used to enzymatically degrade cell surface HS GAGs. Anticoagulant potential was evaluated using a factor Xa (FXa) activity assay. Knock down of syndecan-3 in endothelial,- smooth muscle- and breast cancer cells reduced the TFPI surface levels by 20-50%, and an association of TFPIα to syndecan-3 on the cell surface was demonstrated. Western blotting indicated that TFPIα was found in complex with syndecan-3. The TFPI bound to syndecan-3 did not inhibit the FXa generation. Removal of HS GAGs did not release TFPI antigen from the cells.

conclusionsWe demonstrated an association between TFPIα and syndecan-3 in vascular cells and in cancer cells, which did not appear to depend on HS GAGs. No anticoagulant activity was detected for the TFPI associated with syndecan-3, which may indicate coagulation independent functions for this cell associated TFPI pool. This will, however, require further investigation.

Indexed as

Breast NeoplasmsCell Line, TumorEndothelial CellsFactor VIIaGene Expression RegulationGene Knockdown TechniquesHumansLipoproteinsMyocytes, Smooth MuscleProtein TransportRNA, MessengerSyndecan-3Factor VIIalipoprotein-associated coagulation inhibitorLipoproteinsRNA, MessengerSDC3 protein, humanSyndecan-3

Identifiers

PMID25617766
PMCPMC4305309
OpenAlexW2009689041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.